1.The Prevalence of Barrett's Esophagus and the Comparison of Barrett's Esophagus with Cardiac Intestinal Metaplasia in the Health Screening at a Secondary Care Hospital.
Cheul Young CHOI ; Seungchul SUH ; Jae Serk PARK ; Hyun Jeong LEE ; Jong Sup LEE ; Hyo Sun CHOI ; Hyun Sung PARK ; Seung Goun HONG
The Korean Journal of Gastroenterology 2012;60(4):219-223
BACKGROUND/AIMS: The purpose of this study was to estimate the prevalence of Barrett's esophagus (BE) and its association with reflux esophagitis (RE) and peptic ulcer disease detected by free charge endoscopy which was covered by the National Health Insurance at a secondary care hospital, and to compare the results of the biopsy of BE with that of cardiac intestinal metaplasia (CIM). METHODS: A total of 4,002 patients underwent endoscopy from March 2010 to December 2012. BE was diagnosed if there was histologically proven specialized intestinal metaplasia, and CIM was diagnosed if intestinal metaplasia was accompanied with chronic gastritis. RESULTS: Four hundred twenty four patients underwent endoscopic biopsy, and the prevalence of BE was 1.0% (42/4,002). The mean age and the proportion of males in BE were significantly higher than those of the rest of study population, and BE had slight tendency related to RE than the rest of study population. CIM was observed in 34 patients and BE and CIM showed similar results, regarding age, sex and association with RE. The mean length of endoscopic Barrett's mucosa of BE group was 9.2+/-5.1 mm, and it was similar to that of CIM. CONCLUSIONS: The prevalence of BE in the secondary care hospital was not low, and old age and male sex were significantly associated with BE. Because BE was observed in about 10% of biopsied patients and CIM was observed in a similar percentage with BE, the precise targeted biopsy is warranted and the biopsy method should be reestablished through the large prospective study of multiple secondary care hospitals.
Adult
;
Aged
;
Aged, 80 and over
;
Barrett Esophagus/complications/epidemiology/*pathology
;
Duodenal Ulcer/complications/epidemiology/pathology
;
Esophagoscopy
;
Female
;
Gastroesophageal Reflux/complications/epidemiology/pathology
;
Hospitals
;
Humans
;
Male
;
Metaplasia/complications/epidemiology/*pathology
;
Middle Aged
;
Prevalence
;
Secondary Care
;
Stomach Ulcer/complications/epidemiology/pathology
2.Changes in Upper Gastrointestinal Diseases according to Improvement of Helicobacter pylori Prevalence Rate in Korea.
The Korean Journal of Gastroenterology 2015;65(4):199-204
Helicobacter pylori can cause variety of upper gastrointestinal disorders such as peptic ulcer, mucosa associated lymphoid tissue (MALT)-lymphoma, and gastric cancer. The prevalence of H. pylori infection has significantly decreased in Korea since 1998 owing to active eradication of H. pylori. Along with its decrease, the prevalence of peptic ulcer has also decreased. However, the mean age of gastric ulcer increased and this is considered to be due to increase in NSAID prescription. Gastric cancer is one of the leading causes of cancer deaths in Korea and Japan, and IARC/WHO has classified H. pylori as class one carcinogen of gastric cancer. Despite the decreasing prevalence of H. pylori infection, the total number of gastric cancer in Korea has continuously increased from 2006 to 2011. Nevertheless, the 5 year survival rate of gastric cancer patients significantly increased from 42.8% in 1993 to 67% in 2010. This increase in survival rate seems to be mainly due to early detection of gastric cancer and endoscopic mucosal dissection treatment. Based on these findings, the prevalence of peptic ulcer is expected to decrease even more with H. pylori eradication therapy and NSAID will become the main cause of peptic ulcer. Although the prevalence of gastric cancer has not changed along with decreased the prevalence of H. pylori, gastric cancer is expected to decrease in the long run with the help of eradication therapy and endoscopic treatment of precancerous lesions.
Anti-Bacterial Agents/therapeutic use
;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects
;
Gastrointestinal Diseases/complications/*epidemiology
;
Helicobacter Infections/complications/drug therapy/epidemiology
;
Humans
;
Lymphoma, B-Cell, Marginal Zone/epidemiology
;
Peptic Ulcer/epidemiology/etiology
;
Prevalence
;
Stomach Neoplasms/etiology/mortality/pathology